liefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)PRO-DEX, INC. and SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(unaudited)December 31, 2010
June 30, 2010ASSETSCurrent assets:Cash and cash equivalents
$
2,019,000
$ 3,794,000Accounts receivable, net of allowance for doubtful accountsof $15,000 at December 31, 2010 and $25,000 at June 30, 2010
2,566,000
2,682,000Other current receivables
-
22,000Inventories
3,906,000
3,228,000Prepaid expenses
205,000
174,000Deferred income taxes
209,000
209,000Total current assets
8,905,000
10,109,000Property, plant, equipment and leasehold improvements, net
3,767,000
4,092,000Other assets
60,000
78,000Total assets
$
2,732,000
$ 14,279,000LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable
$
935,000
$ 1,279,000Accrued expenses
1,681,000
1,947,000Income taxes payable
74,000
79,000Current portion of bank term loan
331,000
400,000Current portion of real estate loan
-
35,000Total current liabilities
3,021,000
3,740,000Long-term liabilities:Bank term loan
836,000
967,000Real estate loan
-
1,493,000Deferred income taxes
209,000
209,000Deferred rent
270,000
255,000Total long-term liabilities
1,315,000
2,924,000Total liabilities
4,336,000
6,664,000Commitments and contingencies Shareholders
'/>"/>
SOURCE Pro-Dex, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer2.
Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast3.
Pro-Dex, Inc. Announces Fiscal Second Quarter 2010 Results4.
Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders5.
PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement6.
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock7.
ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company8.
Perrigo Announces Settlement of Rogaine® Foam Patent Litigation9.
Awarepoint Announces First Annual RTLS Customer Conference and User Group Results and Highlights10.
Omeros Announces Publication of Data From Antifibrinolytic Program11.
Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit